Opportunity Information: Apply for PAR 14 255
Apply for PAR 14 255
- The National Institutes of Health in the education food and nutrition health sector is offering a public funding opportunity titled "Multidisciplinary Studies of HIV and Viral Hepatitis Co Infection (R01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.242 Mental Health Research Grants 93.273 Alcohol Research Programs 93.279 Drug Abuse and Addiction Research Programs 93.393 Cancer Cause and Prevention Research 93.394 Cancer Detection and Diagnosis Research 93.395 Cancer Treatment Research 93.396 Cancer Biology Research 93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research 93.855 Allergy and Infectious Diseases Research 93.856 Microbiology and Infectious Diseases Research.
- This funding opportunity was created on Jun 10, 2014 and posted on Jun 10, 2014.
- Applicants must submit their applications by May 7, 2017. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: Special district governments Independent school districts For profit organizations other than small businesses Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Public housing authorities/Indian housing authorities Private institutions of higher education Others (see text field entitled Additional Information on Eligibility for clarification) State governments City or township governments Native American tribal organizations (other than Federally recognized tribal governments) County governments Small businesses Public and State controlled institutions of higher education Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Native American tribal governments (Federally recognized).
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Asian American Native American Pacific Islander Serving Institutions (AANAPISISs) Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Non domestic (non U.S.) Entities (Foreign Organizations) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession Non domestic (non U.S.) Entities (Foreign Institutions) are eligible to apply. Non domestic (non U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Multidisciplinary Studies of HIV and Viral Hepatitis Co-Infection (R01) funding opportunity (PAR-14-255) was a National Institutes of Health (NIH) discretionary grant program designed to support research that closes key knowledge gaps about people living with both HIV and viral hepatitis. The central goal was to encourage multidisciplinary, mechanistic, clinical, and population-focused studies that clarify how HIV and hepatitis viruses interact biologically, what health complications are most strongly linked to co-infection, and how well newer hepatitis C treatments work in the specific context of HIV/HCV co-infection. The FOA explicitly aligns with federal priorities laid out in the 2011 HHS Action Plan for the Prevention, Care, and Treatment of Viral Hepatitis, reflecting an emphasis on reducing the burden of viral hepatitis and improving outcomes for affected populations.
The research scope emphasized three main themes. First, it sought studies on pathogenic interactions between HIV and hepatitis viruses, meaning projects that explain how co-infection changes disease processes compared with having either infection alone. This can include work on immune dysfunction, viral dynamics, inflammation, liver injury pathways, and other biological mechanisms that could explain accelerated disease progression or altered treatment responses. Second, it targeted co-morbidities associated with HIV/hepatitis co-infection. In practice, that could span liver-related outcomes (like fibrosis progression, cirrhosis, hepatocellular carcinoma risk) as well as extrahepatic or systemic complications that may be amplified by chronic infection and immune activation. Third, it highlighted the need to evaluate the effectiveness of interferon-free direct-acting antiviral (DAA) regimens for treating HIV/HCV co-infection. At the time this FOA was active, interferon-free DAAs represented a major shift in HCV care, so the announcement encouraged evidence on real-world and clinical effectiveness, including outcomes that matter specifically in co-infected patients, such as drug-drug interactions with antiretroviral therapy, adherence considerations, safety, sustained virologic response rates, and longer-term impacts on liver and overall health.
Administratively, this opportunity used the NIH R01 mechanism, meaning it was structured to fund substantial, hypothesis-driven research projects that could be investigator-initiated and carried out over multiple years. There was no cost-sharing or matching requirement, which is typical of NIH research grants and lowers barriers for applicants by not requiring them to contribute non-federal funds as a condition of award. The FOA fell under a broad set of NIH-related funding activity categories tied to health and biomedical research, with CFDA program associations spanning infectious diseases and microbiology, allergy and infectious diseases, mental health, alcohol and drug abuse research, cancer-related research, and diabetes/digestive/kidney diseases. That spread of CFDA numbers signals that NIH viewed HIV/hepatitis co-infection as a cross-cutting issue touching multiple organ systems and research communities rather than a narrow topic limited to hepatology or virology.
Eligibility was intentionally wide to attract diverse institutions and perspectives. Eligible applicants included federal, state, county, city, and special district governments; tribal governments and tribal organizations; public and private institutions of higher education; nonprofit organizations with and without 501(c)(3) status; for-profit organizations (including those other than small businesses); public housing authorities/Indian housing authorities; and a range of community-based and faith-based organizations where appropriate. The FOA also explicitly welcomed applications from institutions serving historically underrepresented groups, including HBCUs, Hispanic-serving institutions, AANAPISIs, tribally controlled colleges and universities, and Alaska Native and Native Hawaiian serving institutions. Importantly, non-U.S. entities (foreign organizations and foreign institutions) were eligible, non-U.S. components of U.S. organizations could apply, and foreign components were allowed as defined by the NIH Grants Policy Statement. This international eligibility reflects the global nature of HIV and viral hepatitis burdens and the value of studying co-infection across varied settings and populations.
Key dates show that the opportunity was posted and created on June 10, 2014, with an original and final closing date of May 7, 2017, and an archive date of June 7, 2017. In other words, it is no longer an active open solicitation, but it remains a useful reference point for the kinds of projects NIH prioritized during the rapid transition to interferon-free HCV therapy. The primary agency contact pathway referenced the NIH Office of Extramural Research (OER) web support for access or linking issues, and the full announcement was hosted on the NIH grants policy/guide site at the provided URL.
Overall, PAR-14-255 aimed to push the field beyond basic descriptions of co-infection and toward integrated, evidence-driven understanding of mechanisms, clinical consequences, and modern treatment effectiveness for HIV and viral hepatitis co-infected populations, with broad eligibility intended to stimulate collaboration across disciplines, sectors, and countries.
Frequently Asked Questions (FAQs)
What is PAR-14-255?
PAR-14-255 is the Funding Opportunity Announcement (FOA) titled "Multidisciplinary Studies of HIV and Viral Hepatitis Co-Infection (R01)." It was a National Institutes of Health (NIH) discretionary grant program that supported research focused on people living with both HIV and viral hepatitis.
What was the main purpose of this funding opportunity?
The central purpose was to close key knowledge gaps about HIV and viral hepatitis co-infection by encouraging multidisciplinary research. The FOA emphasized mechanistic, clinical, and population-focused studies that explain how HIV and hepatitis viruses interact, what health complications are most strongly linked to co-infection, and how well newer hepatitis C therapies perform in the specific context of HIV/HCV co-infection.
What types of research approaches did the FOA encourage?
The FOA encouraged multidisciplinary approaches, including mechanistic studies (biological pathways and disease processes), clinical research (patient-centered outcomes and treatment considerations), and population-focused studies (patterns and outcomes across groups and settings).
What were the main scientific themes or topic areas emphasized?
The research scope emphasized three themes: (1) pathogenic interactions between HIV and hepatitis viruses, (2) co-morbidities associated with HIV/hepatitis co-infection, and (3) effectiveness of interferon-free direct-acting antiviral (DAA) regimens for HIV/HCV co-infected patients.
What does "pathogenic interactions" mean in this FOA?
In this FOA, "pathogenic interactions" refers to research that explains how having both HIV and hepatitis virus infection changes disease processes compared to having either infection alone. Examples of mechanisms mentioned include immune dysfunction, viral dynamics, inflammation, and liver injury pathways that could contribute to accelerated disease progression or altered treatment response in co-infected individuals.
What kinds of co-morbidities were in scope for this opportunity?
The FOA highlighted co-morbidities associated with HIV/hepatitis co-infection, including liver-related outcomes such as fibrosis progression, cirrhosis, and hepatocellular carcinoma risk. It also noted that extrahepatic or systemic complications could be relevant, particularly those amplified by chronic infection and immune activation.
Why did the FOA emphasize interferon-free direct-acting antivirals (DAAs) for HCV?
At the time the FOA was active, interferon-free DAAs represented a major shift in hepatitis C care. The FOA encouraged evidence on real-world and clinical effectiveness of these regimens specifically for HIV/HCV co-infected patients.
What outcomes or considerations related to DAA treatment were specifically highlighted?
The FOA highlighted outcomes and considerations relevant to HIV/HCV co-infected patients, including drug-drug interactions with antiretroviral therapy, adherence considerations, safety, sustained virologic response (SVR) rates, and longer-term impacts on liver health and overall health.
What grant mechanism did PAR-14-255 use?
This opportunity used the NIH R01 mechanism, which is designed to fund substantial, hypothesis-driven, investigator-initiated research projects that may be carried out over multiple years.
Was cost-sharing or matching required?
No. The FOA stated that there was no cost-sharing or matching requirement, which is typical for NIH research grants.
How does this FOA align with federal priorities?
The FOA explicitly aligned with federal priorities described in the 2011 HHS Action Plan for the Prevention, Care, and Treatment of Viral Hepatitis, reflecting an emphasis on reducing the burden of viral hepatitis and improving outcomes for affected populations.
Which NIH-related research areas or program associations were connected to this FOA?
The FOA was associated with a broad set of NIH-related funding activity categories and CFDA program associations spanning infectious diseases and microbiology, allergy and infectious diseases, mental health, alcohol and drug abuse research, cancer-related research, and diabetes/digestive/kidney diseases. This reflected the cross-cutting nature of HIV/hepatitis co-infection across multiple organ systems and research communities.
Who was eligible to apply?
Eligibility was intentionally broad. Eligible applicants included federal, state, county, city, and special district governments; tribal governments and tribal organizations; public and private institutions of higher education; nonprofit organizations with and without 501(c)(3) status; for-profit organizations (including those other than small businesses); public housing authorities/Indian housing authorities; and community-based and faith-based organizations where appropriate.
Were institutions serving underrepresented groups encouraged to apply?
Yes. The FOA explicitly welcomed applications from institutions serving historically underrepresented groups, including HBCUs, Hispanic-serving institutions, AANAPISIs, tribally controlled colleges and universities, and Alaska Native and Native Hawaiian serving institutions.
Were non-U.S. (foreign) organizations eligible?
Yes. Non-U.S. entities (foreign organizations and foreign institutions) were eligible. Non-U.S. components of U.S. organizations could apply, and foreign components were allowed as defined by the NIH Grants Policy Statement.
Is PAR-14-255 still open for applications?
No. The FOA is no longer an active open solicitation. It was posted/created on June 10, 2014, had an original and final closing date of May 7, 2017, and an archive date of June 7, 2017.
When was the funding opportunity posted, and when did it close?
The FOA was posted and created on June 10, 2014. The original and final closing date was May 7, 2017, and it was archived on June 7, 2017.
What is the value of PAR-14-255 as a reference today if it is archived?
Based on the provided description, it remains a useful reference point for understanding the kinds of HIV/viral hepatitis co-infection projects NIH prioritized during the period when hepatitis C care was rapidly transitioning to interferon-free DAA therapy.
Where was the full announcement hosted?
The full announcement was hosted on the NIH grants policy/guide site at the provided URL.
Who was listed as the primary agency contact pathway for support?
The FOA referenced the NIH Office of Extramural Research (OER) web support contact pathway for access or linking issues.
What overall impact was PAR-14-255 intended to have on the field?
Overall, PAR-14-255 aimed to move the field beyond basic descriptions of co-infection and toward an integrated, evidence-driven understanding of biological mechanisms, clinical consequences, and modern treatment effectiveness for populations living with both HIV and viral hepatitis, using broad eligibility to stimulate collaboration across disciplines, sectors, and countries.
Browse more opportunities from the same agency: National Institutes of Health
Browse more opportunities from the same category: Education Food and Nutrition Health
Next opportunity: Multidisciplinary Studies of HIV and Viral Hepatitis Co Infection (R21)
Previous opportunity: Cooperative Agreement to Support Navigators in Federally facilitated and State Partnership Marketplaces
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 14 255
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 14 255) also looked into and applied for these:
| Funding Opportunity |
|---|
| Multidisciplinary Studies of HIV and Viral Hepatitis Co Infection (R21) Apply for PAR 14 254 Funding Number: PAR 14 254 Agency: National Institutes of Health Category: Education Food and Nutrition Health Funding Amount: $275,000 |
| Long Term Outcomes of Bariatric Surgery Using Large Datasets (R01) Apply for PAR 14 262 Funding Number: PAR 14 262 Agency: National Institutes of Health Category: Education Food and Nutrition Health Funding Amount: $500,000 |
| Advancing Interventions to Improve Medication Adherence (R01) Apply for PA 14 334 Funding Number: PA 14 334 Agency: National Institutes of Health Category: Education Food and Nutrition Health Funding Amount: Case Dependent |
| Consortium for the Study of Chronic Pancreatitis, Diabetes and Pancreatic Cancer Clinical Centers (CSCPDPC CCs) (U01) Apply for RFA DK 14 027 Funding Number: RFA DK 14 027 Agency: National Institutes of Health Category: Education Food and Nutrition Health Funding Amount: $270,000 |
| Consortium for the Study of Chronic Pancreatitis, Diabetes and Pancreatic Cancer Coordination and Data Management Center (CSCPDPC CDMC) (U01) Apply for RFA DK 14 028 Funding Number: RFA DK 14 028 Agency: National Institutes of Health Category: Education Food and Nutrition Health Funding Amount: $1,000,000 |
| Administrative Supplements for Common Basic Sociobehavioral Mechanisms and Processes that Facilitate or Impede Self Management of Chronic Conditions (Admin Supp) Apply for PA 15 122 Funding Number: PA 15 122 Agency: National Institutes of Health Category: Education Food and Nutrition Health Funding Amount: $100,000 |
| Limited Competition for Renewal Applications Collaborating Centers of Excellence in Regulatory Science and Innovation (U01) Apply for RFA FD 15 009 Funding Number: RFA FD 15 009 Agency: Food Drug Administration Category: Education Food and Nutrition Health Funding Amount: $250,000 |
| Neuroimaging in Obesity Research (R01) Apply for RFA DK 08 009 Funding Number: RFA DK 08 009 Agency: National Institutes of Health Category: Education Food and Nutrition Health Funding Amount: Case Dependent |
| Endoscopic Clinical Research In Pancreatic And Biliary Diseases (R03) Apply for PAR 06 171 Funding Number: PAR 06 171 Agency: National Institutes of Health Category: Education Food and Nutrition Health Funding Amount: $50,000 |
| Exploratory/Developmental Clinical Research Grants in Obesity (R21) Apply for PA 06 256 Funding Number: PA 06 256 Agency: National Institutes of Health Category: Education Food and Nutrition Health Funding Amount: $200,000 |
| Diet, Epigenetic Events, and Cancer Prevention (R21) Apply for PA 06 413 Funding Number: PA 06 413 Agency: National Institutes of Health Category: Education Food and Nutrition Health Funding Amount: $200,000 |
| Diet, Epigenetic Events, and Cancer Prevention (R03) Apply for PA 06 414 Funding Number: PA 06 414 Agency: National Institutes of Health Category: Education Food and Nutrition Health Funding Amount: $50,000 |
| Mechanisms of Alcohol and Drug InducedPancreatitis (R01) Apply for PA 07 067 Funding Number: PA 07 067 Agency: National Institutes of Health Category: Education Food and Nutrition Health Funding Amount: Case Dependent |
| Diet, Epigenetic Events, and Cancer Prevention (R01) Apply for PA 07 175 Funding Number: PA 07 175 Agency: National Institutes of Health Category: Education Food and Nutrition Health Funding Amount: Case Dependent |
| Application of Metabolomics for Translational and Biological Research (R01) Apply for PA 07 301 Funding Number: PA 07 301 Agency: National Institutes of Health Category: Education Food and Nutrition Health Funding Amount: Case Dependent |
| Application of Metabolomics for Translational and Biological Research (R21) Apply for PA 07 302 Funding Number: PA 07 302 Agency: National Institutes of Health Category: Education Food and Nutrition Health Funding Amount: Case Dependent |
| Development of Assays for High Throughput Drug Screening (R01) Apply for PA 07 320 Funding Number: PA 07 320 Agency: National Institutes of Health Category: Education Food and Nutrition Health Funding Amount: Case Dependent |
| Research on the Economics of Diet, Activity, and Energy Balance (R01) Apply for PA 08 078 Funding Number: PA 08 078 Agency: National Institutes of Health Category: Education Food and Nutrition Health Funding Amount: Case Dependent |
| The Effect of Racial and Ethnic Discrimination/Bias on Health Care Delivery (R01) Apply for PA 08 083 Funding Number: PA 08 083 Agency: National Institutes of Health Category: Education Food and Nutrition Health Funding Amount: Case Dependent |
| Etiology, Prevention, and Treatment of Hepatocellular Carcinoma (R01) Apply for PA 08 243 Funding Number: PA 08 243 Agency: National Institutes of Health Category: Education Food and Nutrition Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 14 255", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.